Grantham, Mayo, Van Otterloo & Co (GMO)’s AstraZeneca AZN Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-14,350	Closed	-$1.01M	–	530
2018 Q2	$1.01M	Sell	14,350 -250	-2%	-$18K	0.01%	366
2018 Q1	$1.02M	Sell	14,600 -1,900	-12%	-$132K	0.01%	374
2017 Q4	$1.15M	Buy	16,500 +7,100	+76%	+$479K	0.01%	355
2017 Q3	$637K	Buy	+9,400	New	+$594K	﹤0.01%	404
2017 Q1	–	Sell	-120,316	Closed	-$6.57M	–	584
2016 Q4	$6.57M	Sell	120,316 -177,084	-60%	-$10.1M	0.04%	224
2016 Q3	$19.5M	Buy	297,400 +3,800	+1%	+$248K	0.09%	161
2016 Q2	$17.7M	Buy	293,600 +89,450	+44%	+$5.2M	0.07%	178
2016 Q1	$11.5M	Buy	+204,150	New	+$12.3M	0.04%	227
2014 Q3	–	Sell	-28,000	Closed	-$2.08M	–	435
2014 Q2	$2.08M	Buy	+28,000	New	+$2.02M	0.01%	362

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s AZN Position: Q3 2018 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of AstraZeneca (AZN) in Q3 2018, closing a stake of 14,350 shares — an estimated $1.01M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in AZN in Q2 2014 and held it in 9 quarters. The position peaked at $19.5M in Q3 2016. 544 funds tracked by Wall St. Rank hold AZN as of Q3 2018.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining AstraZeneca position as of Q3 2018 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 14,350 AstraZeneca shares in Q3 2018, an estimated $1.01M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in AstraZeneca in Q2 2014 and held it in 9 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s AstraZeneca position peaked at $19.5M in Q3 2016.
544 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2018.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2018, filed 14 Nov 2018.